Evidence map›Paper›PMID 37234171›Full record

ArticleFrontiers in immunology2023

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.

Taiyu Shang, Tianyi Jiang, Tao Lu, Hui Wang, Xiaowen Cui, Yufei Pan, Mengyou Xu, Mengmiao Pei, Zhiwen Ding, Xiaofan Feng and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Taiyu ShangNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Tianyi JiangNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Tao LuDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Hui WangDepartment of Hepatobiliary Diseases, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Xiaowen CuiNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Yufei PanNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Mengyou XuNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Mengmiao PeiNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Zhiwen DingNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Xiaofan FengNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Yunkai LinNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Xin LiDepartment of Hepatobiliary Diseases, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yexiong TanNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Feiling FengDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Hui DongDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Hongyang WangNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Liwei DongNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Second Military Medical University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cholangiocarcinoma (CCA) is a malignant tumor of the biliary epithelium with a poor prognosis. The lack of biomarkers to predict therapeutic response and prognosis is one of the major challenges for CCA treatment. Tertiary lymphoid structures (TLS) provide a local and pivotal microenvironment for tumor immune responses. The prognostic value and clinical relevance of TLS in CCA remain unclear. We aimed to explore the characteristics and clinical significance of TLS in CCA. Methods: We investigated the prognostic value and clinical relevance of TLS in CCA using a surgery cohort containing 471 CCA patients (cohort 1) and an immunotherapy cohort containing 100 CCA patients (cohort 2). Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were used to evaluate the maturity of TLS. Multiplex IHC (mIHC) was employed to characterize the composition of TLS. Results: Different maturity of TLS were observed in CCA tissue sections. Strong staining of the four-gene signature including PAX5, TCL1A, TNFRSF13C, and CD79A were found in TLS regions. A high density of intra-tumoral TLS (T-score high) were significantly correlated with longer overall survival (OS) both in CCA cohort 1 (p = 0.002) and cohort 2 (p = 0.01), whereas a high density of peri-tumoral TLS (P-score high) were associated with shorter OS in these two cohorts (p = 0.003 and p = 0.03, respectively). Conclusion: The established four-gene signature efficiently identified the TLS in CCA tissues. The abundance and spatial distribution of TLS were significantly correlated with the prognosis and immune checkpoint inhibitors (ICIs) immunotherapy response of CCA patients. The presence of intra-tumoral TLS are positive prognostic factors for CCA, which provide a theoretical basis for the future diagnosis and treatment of CCA.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaTertiary Lymphoid StructuresBile Ducts, IntrahepaticHumansImmunotherapyPrognosisTumor Microenvironmentcholangiocarcinomaimmune checkpoint inhibitorsprognosistertiary lymphoid structurestumor microenvironment

Identifiers

PMID37234171
PMCPMC10206168
OpenAlexW4378348553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.